Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$3700.00
-95.00 (-2.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-27.9B · quality 25.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$182.1B
P/E
34.7x
↑EV/EBITDA
7.7x
↓ROE
11.1%
↑Gross Margin
36.5%
↓Debt/Equity
1.35
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+16.2%
FCF CAGR
—
FCF margin
-3.0%
FCF / Net income
-0.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $259.59B · net income $18.99B · FCF $-7.82B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $259.59B | $259.59B | $227.93B | $208.86B | $165.62B |
| Net Income | $18.99B | $18.99B | $16.17B | $2.20B | $15.91B |
| EBITDA | $48.06B | $48.06B | $43.29B | $24.65B | $33.43B |
| EPS | 385.71 | 385.71 | 328.59 | 44.72 | 316.19 |
| Gross Margin | 36.5% | 36.5% | 35.7% | 34.8% | 42.4% |
| Operating Margin | 9.0% | 9.0% | 7.7% | 2.6% | 11.6% |
| Net Margin | 7.3% | 7.3% | 7.1% | 1.1% | 9.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.35 | 1.35 | 1.30 | 1.18 | 1.06 |
| Current Ratio | 2.76 | 2.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.82B | $-7.82B | $-31.11B | $-27.93B | $8.55B |
| Returns | |||||
| ROE | 11.1% | 11.1% | 10.4% | 1.6% | 12.0% |
| Valuation | |||||
| P/E | 34.65 | 34.65 | 8.35 | 42.40 | 8.35 |
| EV/EBITDA | 7.65 | 7.65 | 7.13 | 9.35 | 7.20 |
| P/B | 1.06 | 1.06 | 0.87 | 0.68 | 1.01 |
| Growth & Yield | |||||
| Revenue Growth | 13.9% | 13.9% | 9.1% | 26.1% | — |
| EPS Growth | 17.4% | 17.4% | 634.8% | -85.9% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-5.2%
EPS terminal req.
$328.31
Spread vs growth
22.6%
5Y implied EPS CAGR
0.6%
EPS terminal req.
$397.26
Spread vs growth
16.8%
10Y implied EPS CAGR
5.2%
EPS terminal req.
$639.79
Spread vs growth
12.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+38.1%
Start / end P/E
8.6x → 10.0x
EPS bridge
328.59 → 385.71
Residual
+2.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.